Skip to main content

Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs

Bloomberg BNA

Aug
5
2015

Date: August 5, 2015

Time: 9:00AM - 10:00AM

Topics

  • Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs

Mintz Levin attorneys Ellyn Sternfield, Theresa Carnegie, and Joanne Hawana will be presenting a Bloomberg BNA Webinar entitled, "Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs?" on August 5th. They discuss the state action on biosimilars, potential cost savings for Health Care Programs, the role of the FDA, and the CMS guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products.

Educational Objectives:

  • Discuss the state action on biosimilars
  • Explore potential cost savings for health care programs
  • Address the role of the Federal Drug Administration’s approval of biosimilar drug products
  • Review the Centers for Medicare and Medicaid services guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products

Speakers

Theresa advises clients on all aspects of the pharmaceutical supply chain. Her practice involves counseling industry stakeholders on a range of business, legal, transactional, and compliance matters.
Ellyn L. Sternfield is a Mintz Special Counsel with an extensive background in government health care enforcement. She provides insight to clients with compliance concerns and helps clients facing potential state or federal investigations.
Professional Cropped Hawana Joanne Mintz

Joanne S. Hawana

Panelist

Joanne counsels global clients on the regulatory and distribution-related implications when bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized.